After the rights issue is complete, imo the share price will move upwards again to around the 2.50-2.80 range and wait for news, not just the next implant because that's a given and already priced in.
The next substantial move above $3.00 imo, will come once the last patient is implanted, whatever number that is. The market won't be aware until the company's made an announcement that it's reached the number of patients needed for sufficient proof that the product works, but as number of successful patients increases the market will suspect we're getting close. The stock will be re-rated and hopefully fund managers will move in a substantial way, until overseas trials start and then wait for another explosive run with % like we've seen from Jun - Sept.
VCR
ventracor limited
